Cargando…
Farnesysltransferase Inhibitor Prevents Burn Injury-Induced Metabolome Changes in Muscle
Burn injury remains a significant public health issue worldwide. Metabolic derangements are a major complication of burn injury and negatively affect the clinical outcomes of severely burned patients. These metabolic aberrations include muscle wasting, hypermetabolism, hyperglycemia, hyperlactatemia...
Autores principales: | Nakazawa, Harumasa, Wong, Lai Ping, Shelton, Laura, Sadreyev, Ruslan, Kaneki, Masao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506277/ https://www.ncbi.nlm.nih.gov/pubmed/36144205 http://dx.doi.org/10.3390/metabo12090800 |
Ejemplares similares
-
Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018) -
Protective effects of farnesyltransferase inhibitor on sepsis-induced morphological aberrations of mitochondria in muscle and increased circulating mitochondrial DNA levels in mice
por: Tsuji, Daisuke, et al.
Publicado: (2021) -
Role of Protein Farnesylation in Burn-Induced Metabolic Derangements and Insulin Resistance in Mouse Skeletal Muscle
por: Nakazawa, Harumasa, et al.
Publicado: (2015) -
Bioavailability of Reduced Coenzyme Q10 (Ubiquinol-10) in Burn Patients
por: Kuriyama, Naohide, et al.
Publicado: (2022) -
Coenzyme Q10 protects against burn‐induced mitochondrial dysfunction and impaired insulin signaling in mouse skeletal muscle
por: Nakazawa, Harumasa, et al.
Publicado: (2019)